From$59
Consult—
Prescription—
Shipping—
Overview
Sesame Care brings a marketplace model to telehealth that gives patients something most GLP-1 platforms do not: real choice in their clinician. Rather than assigning you to whoever is available in an algorithmic queue, Sesame’s network lets patients browse and select providers based on specialty, availability, and pricing, giving you more control over your care relationship. Sesame Care is a telehealth marketplace that lets you choose your own clinician for oral GLP-1 weight loss care, with flexible appointments and clear pricing. Ongoing video visits, dedicated provider care, labs & messaging for as low as $59/mo* | Cash-pay GLP-1 medications as low as $149/mo | Insurance accepted for weight loss medications | *Based on a 12-month Success by Sesame commitment | In 3 months | In 6 months | In 12 months | Results may vary. Milestones are based on a study of injectable semaglutide 2.4 mg in non-diabetic adults with obesity (BMI≥30) or overweight (BMI ≥27 with ≥1 weight-related condition), when paired with healthy lifestyle changes. | Medication costs are not included in the subscription price and will vary based on your insurance status and pharmacy. | Cash pay prices (without insurance) | In-network price (with insurance) | Cash pay prices (without insurance) | Semaglutide | $149 | Price with insurance: as low as | $25 | Price without insurance: | $149 | (1.5mg, 4mg) or $299/mo (9mg, 25mg) | Wegovy® pill is the first-ever oral GLP-1 medication for weight loss. It is FDA-approved to treat adults with obesity, or with overweight who also have weight-related medical problems. | Tirzepatide | $299 | Price with insurance: as low as | $25 | Price without insurance: | $299 | (2.5mg), $398/mo (5mg), $499/mo (7.5mg), $698/mo (10mg, 12.5mg, 15mg) | The Zepbound KwikPen® is a multi-dose injectable pen that contains Zepbound (tirzepatide), a medication that is FDA-approved to treat adults with obesity or overweight with weight-related conditions. Each pen contains a full…
Sesame Care
Ongoing video visits, dedicated provider care, labs & messaging for as low as $59/mo* | Cash-pay GLP-1 medications as low as $149/mo | Insurance accepted for weight loss medications | *Based on a 12-month Success by Sesame commitment | In 3 months | In 6 months | In 12 months | Results may vary. Milestones are based on a study of injectable semaglutide 2.4 mg in non-diabetic adults with obesity (BMI≥30) or overweight (BMI ≥27 with ≥1 weight-related condition), when paired with healthy lifestyle changes. | Medication costs are not included in the subscription price and will vary based on your insurance status and pharmacy. | Cash pay prices (without insurance) | In-network price (with insurance) | Cash pay prices (without insurance) | Semaglutide | $149 | Price with insurance: as low as | $25 | Price without insurance: | $149 | (1.5mg, 4mg) or $299/mo (9mg, 25mg) | Wegovy® pill is the first-ever oral GLP-1 medication for weight loss. It is FDA-approved to treat adults with obesity, or with overweight who also have weight-related medical problems. | Tirzepatide | $299 | Price with insurance: as low as | $25 | Price without insurance: | $299 | (2.5mg), $398/mo (5mg), $499/mo (7.5mg), $698/mo (10mg, 12.5mg, 15mg) | The Zepbound KwikPen® is a multi-dose injectable pen that contains Zepbound (tirzepatide), a medication that is FDA-approved to treat adults with obesity or overweight with weight-related conditions. Each pen contains a full month's supply of 4 doses (one injection per week). It comes in 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg strengths.
Visit Site
Pros
- Easy booking
- Broad treatment coverage
Cons
- Experience can vary by clinician
Features
- Large clinician network
- Flexible scheduling
- Nationwide access in many states
Best for: People who want broad telehealth choice
Sesame Care
Ongoing video visits, dedicated provider care, labs & messaging for as low as $59/mo* | Cash-pay GLP-1 medications as low as $149/mo | Insurance accepted for weight loss medications | *Based on a 12-month Success by Sesame commitment | In 3 months | In 6 months | In 12 months | Results may vary. Milestones are based on a study of injectable semaglutide 2.4 mg in non-diabetic adults with obesity (BMI≥30) or overweight (BMI ≥27 with ≥1 weight-related condition), when paired with healthy lifestyle changes. | Medication costs are not included in the subscription price and will vary based on your insurance status and pharmacy. | Cash pay prices (without insurance) | In-network price (with insurance) | Cash pay prices (without insurance) | Semaglutide | $149 | Price with insurance: as low as | $25 | Price without insurance: | $149 | (1.5mg, 4mg) or $299/mo (9mg, 25mg) | Wegovy® pill is the first-ever oral GLP-1 medication for weight loss. It is FDA-approved to treat adults with obesity, or with overweight who also have weight-related medical problems. | Tirzepatide | $299 | Price with insurance: as low as | $25 | Price without insurance: | $299 | (2.5mg), $398/mo (5mg), $499/mo (7.5mg), $698/mo (10mg, 12.5mg, 15mg) | The Zepbound KwikPen® is a multi-dose injectable pen that contains Zepbound (tirzepatide), a medication that is FDA-approved to treat adults with obesity or overweight with weight-related conditions. Each pen contains a full month's supply of 4 doses (one injection per week). It comes in 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg strengths.
Visit Site
Customer Reviews
No customer reviews yet. Be the first to review.
Used this provider? Share your experience.Reviews are published under your account name after moderation.
Ready to try Sesame Care?
Sesame Care is a telehealth marketplace that lets you choose your own clinician for oral GLP-1 weight loss care, with flexible appointments and clear pricing. Ongoing video visits, dedicated provider care, labs & messaging for as low as $59/mo* | Cash-pay GLP-1 medications as low as $149/mo | Insurance accepted for weight loss medications | *Based on a 12-month Success by Sesame commitment | In 3 months | In 6 months | In 12 months | Results may vary. Milestones are based on a study of injectable semaglutide 2.4 mg in non-diabetic adults with obesity (BMI≥30) or overweight (BMI ≥27 with ≥1 weight-related condition), when paired with healthy lifestyle changes.…
Visit Site